Harrison.ai vs Insilico Medicine

Insilico Medicine has a disclosed valuation of $1.2B, while Harrison.ai's valuation is not publicly available, making a direct size comparison difficult. Insilico Medicine employs 350 people.

Insilico Medicine has raised more in total funding at $403M, compared to Harrison.ai's $129M — a gap of $274M. Combined, the two companies have completed 3 known funding rounds.

Harrison.ai holds the higher Awaira Score at 68/100, compared to Insilico Medicine's 67/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 1-point gap that reflects meaningful differences in scale or traction.

Harrison.ai was founded by Aengus Tran in 2018. Insilico Medicine was founded by Alex Zhavoronkov in 2014. Visit each company's profile on Awaira for a full founder biography.

Harrison.ai: Harrison.ai develops AI radiology and pathology analysis software for clinical deployment, building FDA-cleared and TGA-registered algorithms for chest X-ray abnormality detection, CT pulmonary angiography analysis, and mammography screening under its Annalise.ai product brand. The Sydney company focuses on AI clinical decision support that helps radiologists prioritise worklists, detect abnormalities, and reduce reporting errors in high-volume radiology departments.\n\nThe company raised approximately $129 million including a Series C from investors including Blackbird Ventures, Skip Capital, and Telstra Ventures. Harrison.ai has deployed its Annalise.ai platform across Australian hospital networks and has received US FDA clearance for its chest X-ray AI product, enabling international commercial expansion beyond Australia. The company has published clinical validation studies demonstrating AI performance that is non-inferior to specialist radiologist reads on chest X-ray abnormality detection across multiple institutions.\n\nHarrison.ai competes in the AI radiology market against Aidoc, Lunit, Qure.ai, and Behold.ai, which all target radiologist workflow assistance and clinical alerting. The Australian healthcare market provides a strong home base given the National Health Service framework and centrally coordinated radiology procurement, while FDA clearance opens the substantially larger US radiology AI market. The company is considered one of Australia most promising medical AI companies and a flagship for the Australian healthcare technology ecosystem. Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels.

Insilico Medicine was founded first in 2014, giving it 4 years of additional market experience. Harrison.ai was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Harrison.ai has approximately 100-500 employees, while Insilico Medicine has approximately 350. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Harrison.ai and Insilico Medicine are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.